Patient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy
AbstractCandida spp. are colonizing fungi of human skin and mucosae of the gastrointestinal and genitourinary tract, present in 30–50% of healthy individuals in a population at any given moment. The host defense mechanisms prevent this commensal fungus from invading and causing disease. Loss of skin or mucosal barrier function, microbiome imbalances, or defects of immune defense mechanisms can lead to an increased susceptibility to severe mucocutaneous or invasive candidiasis. A comprehensive understanding of the immune defense against Candida is essential for developing adjunctive immunotherapy. The important role of underlying genetic susceptibility to Candida infections has become apparent over the years. In most patients, the cause of increased susceptibility to fungal infections is complex, based on a combination of immune regulation gene polymorphisms together with other non-genetic predisposing factors. Identification of patients with an underlying genetic predisposition could help determine which patients could benefit from prophylactic antifungal treatment or adjunctive immunotherapy. This review will provide an overview of patient susceptibility to mucocutaneous and invasive candidiasis and the potential for adjunctive immunotherapy. View Full-Text
Share & Cite This Article
Davidson, L.; Netea, M.G.; Kullberg, B.J. Patient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy. J. Fungi 2018, 4, 9.
Davidson L, Netea MG, Kullberg BJ. Patient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy. Journal of Fungi. 2018; 4(1):9.Chicago/Turabian Style
Davidson, Linda; Netea, Mihai G.; Kullberg, Bart J. 2018. "Patient Susceptibility to Candidiasis—A Potential for Adjunctive Immunotherapy." J. Fungi 4, no. 1: 9.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.